Pii adds trial scale HME capacity

- Last updated on GMT

Related tags: Economics

Pharmaceutics International (Pii) has expanded its range of formulation and process development services with the addition of bioavailability boosting hot-melt extrusion (HME) capabilities.

The US contract manufacturing organisation (CMO) has purchased two Lititz twin screw extruders, which it said are suitable for pilot-scale production runs for Phase I and II clinical trials.

In a press statement company SVP Steve King said that the new capabilities are a useful addition to Pii’s portfolio of bioavailability enhancing technologies, which include spray drying, solvent-based fluid bed processing, soft gels and liquid capsules.

Pii’s investment, details of which were not disclosed, is the second manufacturing expansion the firm has undertaken this year. In May it added an MG2 G140 capsule filler to its oral manufacturing area.

At the time spokeswoman Elizabeth Hickman told Outsourcing-pharma.com the move was designed to cater for a specific commercial manufacturing contract and to further position Pii for growth.

Related topics: Bioavailability Challenge

Related news